Danaher Raises 2025 Earnings Outlook
Werte in diesem Artikel
Danaher (NYSE:DHR) reported its second-quarter 2025 results on July 22, 2025, with sales of $5.9 billion and core revenue growth of 1.5% year over year. Adjusted diluted EPS grew 5% to $1.80, free cash flow hit $1.1 billion, and management raised full-year adjusted diluted net EPS guidance to $7.70–$7.80. The call addressed the company's CFO succession plan, sector-specific momentum, and notable tariff and China headwinds, and reaffirmed a high single-digit percentage long-term core growth outlook for bioprocessing.Danaher’s biotechnology segment, anchored by its $6 billion bioprocessing business, reported 6% core revenue growth, led by low double-digit percentage consumables growth and robust order trends, particularly from large pharma contract manufacturers. Although equipment sales declined and global trade volatility suppressed larger-scale capital decisions, bioprocessing’s profitability in the first half of 2025 was strong.Sustained high growth in consumables, despite capital spending pauses, significantly enhances Danaher’s recurring revenue visibility. This secures the bioprocessing franchise’s role as the company’s primary long-term growth driver.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Übrigens: Danaher und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Danaher
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Danaher
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: MotleyFool
Nachrichten zu Danaher Corp.
Analysen zu Danaher Corp.
Datum | Rating | Analyst | |
---|---|---|---|
19.07.2019 | Danaher Buy | Needham & Company, LLC | |
30.05.2019 | Danaher Outperform | Wolfe Research | |
17.04.2019 | Danaher Buy | Needham & Company, LLC | |
28.02.2019 | Danaher Buy | Needham & Company, LLC | |
03.01.2019 | Danaher Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
19.07.2019 | Danaher Buy | Needham & Company, LLC | |
30.05.2019 | Danaher Outperform | Wolfe Research | |
17.04.2019 | Danaher Buy | Needham & Company, LLC | |
28.02.2019 | Danaher Buy | Needham & Company, LLC | |
03.01.2019 | Danaher Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
21.04.2017 | Danaher Sector Perform | RBC Capital Markets | |
27.05.2016 | Danaher Sector Perform | RBC Capital Markets | |
22.04.2016 | Danaher Sector Perform | RBC Capital Markets | |
27.01.2016 | Danaher Sector Perform | RBC Capital Markets | |
23.10.2015 | Danaher Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2006 | Danaher underweight | Prudential Financial |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Danaher Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen